Cellebrite DI (CLBT) EBITDA Margin (2020 - 2025)

Cellebrite DI (CLBT) has reported EBITDA Margin for 6 consecutive years, with 16.32% the latest figure, recorded in Q4 2025.

• In Q4 2025, EBITDA Margin fell 288.0% year-over-year to 16.32%; the TTM figure through Dec 2025 stood at 16.49% (down 6423.0% YoY), while the FY2025 annual figure was 16.49%, down 5379.0% from the prior year.
• EBITDA Margin came in at 16.32% for Q4 2025 at Cellebrite DI, up from 15.88% in the prior quarter.
• The five-year high for EBITDA Margin was 194.58% in Q3 2024, with the low at 57.66% in Q1 2023.
• Average EBITDA Margin over 5 years is 28.96%, with a median of 16.1% recorded in 2025.
• Across the five-year window, EBITDA Margin surged 18582 bps in 2024 and tumbled 17871 bps in 2025, its largest moves.
• Year by year, EBITDA Margin stood at 2.14% in 2021, then soared by 418 bps to 11.06% in 2022, then plunged by 236 bps to 15.04% in 2023, then jumped by 228 bps to 19.2% in 2024, then slipped by 15 bps to 16.32% in 2025.
• According to Business Quant data, EBITDA Margin over the past three periods registered 16.32%, 15.88%, and 18.74% for Q4 2025, Q3 2025, and Q2 2025 respectively.